The present invention provides the preparation method for (S)-3-(1-(dimethylamino)ethyl)phenyl ethyl(methyl)carbamate (formula X compound), the preparation methods for its intermediates (S)-1-(3-methoxyphenyl)-N,N-dimethyl-N-((S)-1-phenylethyl)ethanaminium(formula VI compound), (S)-1-(3-hydroxyphenyl)-N,N-dimethyl-N-((S)-1-phenylethyl)ethanaminium(formula VIII compound) and (S)-1-(3-(ethyl(methyl)carbamoyloxy)phenyl)-N,N-dimethyl-N-((S)-1-phenylethyl)ethanaminium (formula IX compound), as well a...

Provided is an oral solid preparation of a compound anti-tubercular drug, wherein the active ingredients are rifampicin, isoniazid, pyrazinamide and ethambutol hydrochloride. The compound oral solid preparation is a coated tablet with coated core or a coated three-layer tablet, wherein the two active ingredients rifampicin and isoniazid do not come to contact with each other directly. The compound oral solid preparation not only improves the stability of the compound preparation, but also improv...

A molecule with neuro activities, especially 4-substituent-2-hydroxylmorpholine-3-one, as a new intermediate of neurokinin-1 receptor antagonist Aprepitant, and preparation method thereof.

The present invention provides a preparation method for N-methyl-N-ethyl-carbamic acid 3-[(S)-1(dimethylamino)ethyl] phenyl ester (as represented by the compound in formula X). The present invention also provides the following intermediates thereof: N-[S)-1-(3-methoxyphenyl)ethyl]-N,N-dimethyl-N-[(S)-1-phenylethylamino] ammonium salt (as represented by the compound in formula VI), N-[(S)-1-(3-hydroxyphenyl)ethyl]-N,N-dimethyl-N-[(S)-1- phenylethylamino] ammonium salt (as represented by the compo...

An oral solid preparation of a compound antituberculosis drug, wherein the active ingredients are rifampicin, isoniazid, pyrazinamide and ethambutol hydrochloride. The compound oral solid preparation is a coated tablet with coated core or a coated three-layer tablet, wherein the two active ingredients rifampicin and isoniazid do not contact directly. The compound oral solid preparation not only improves the stability of the compound preparation, but also improves the bioavailability of rifampici...

The present invention provides a method for separating and purifying a cyclic hexapeptide compound or a pharmaceutically acceptable salt thereof. The cyclohexapeptide compound is preferably caspofungin.

The present invention provides a method for separating and purifying a cyclic hexapeptide compound or a pharmaceutically acceptable salt thereof. The cyclohexapeptide compound is preferably caspofungin.